Confo’s technology enables the discovery of chemical or biological ligands that are conformationally selective. This platform allows Confo to build a multi-indication pipeline of drug candidates with the vision of transforming therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.

Confo Therapeutics was spun out of Vrije Universiteit Brussel in 2015.

In March 2023, Confo announced a worldwide licensing agreement with Eli Lilly for the firm’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554 is an inhibitor of the angiotensin II type 2 receptor (AT2R) in Phase I development.

Confo will receive a $40 million upfront payment from Lilly as well as up to $590 million in potential milestone payments per program, and tiered royalties.